N-(tert-butyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-sulfonamide | 951233-59-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: N-(tert-butyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-sulfonamide
• 英文别名: N-tert-butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-thiophene-2-sulfonamide；N-tert-butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-sulfonamide
• CAS: 951233-59-3
• 化学式: C₁₄H₂₄BNO₄S₂
• 分子量: 345.292
• InChiKey: HMFSWELPLNFWRG-UHFFFAOYSA-N

物化性质

• 沸点：
  460.6±55.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.12
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(tert-butyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-sulfonamide 、 2-bromo-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidin-4-amine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 15.0h， 以66.9%的产率得到N-(tert-butyl)-5-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)thiophene-2-sulfonamide
  参考文献：
  名称：

  Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions

  摘要：

  Drug resistant tuberculosis (TB) infections are on the rise and antibiotics that inhibit Mycobacterium tuberculosis through a novel mechanism could be an important component of evolving TB therapy. Protein kinase A (PknA) and protein kinase B (PknB) are both essential serine-threonine kinases in M. tuberculosis. Given the extensive knowledge base in kinase inhibition, these enzymes present an interesting opportunity for antimycobacterial drug discovery. This study focused on targeting both PknA and PknB while improving the selectivity window over related mammalian kinases. Compounds achieved potent inhibition (K-i approximate to 5 nM) of both PknA and PknB. A binding pocket unique to mycobacterial kinases was identified. Substitutions that filled this pocket resulted in a 100-fold differential against a broad selection of mammalian kinases. Reducing lipophilicity improved antimycobacterial activity with the most potent compounds achieving minimum inhibitory concentrations ranging from 3 to 5 mu M (1-2 mu g/mL) against the H37Ra isolate of M. tuberculosis.

  DOI：

  10.1021/acsmedchemlett.7b00239
• 作为产物：
  描述：

  5-溴噻吩-2-叔丁基磺酰胺 在 对甲苯磺酸 正丁基锂 、 硼酸三异丙酯 作用下， 以 四氢呋喃 、 正己烷 、 甲苯 为溶剂， 反应 6.0h， 生成 N-(tert-butyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-sulfonamide
  参考文献：
  名称：

  WO2008/119689

  摘要：

  公开号：

文献信息

• [EN] PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS<br/>[FR] COMPOSÉS PYRIMIDINE EN TANT QU'INHIBITEURS DE LA TUBERCULOSE
  申请人：VERTEX PHARMA

  公开号：WO2011019405A1

  公开（公告）日：2011-02-17

  The present invention relates to compounds II useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the invention.

  本发明涉及化合物II，用作治疗结核病的抑制剂。该发明还提供了制备本发明化合物的方法。
• Pyridine and pyrimidine derivatives as mGIuR2 antagonists
  申请人：McArthur Silvia Gatti

  公开号：US20070232583A1

  公开（公告）日：2007-10-04

  The present invention relates to compounds of formula (I), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders: wherein A, B, X, Y, R 1 , R 2 , R 3 and R 4 are as defined in the description and claims.

  本发明涉及公式（I）的化合物，其制造过程，包含它们的药物组合物以及它们用于治疗中枢神经系统疾病的用途： 其中A，B，X，Y，R1，R2，R3和R4如描述和要求中所定义。
• PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS
  申请人：Gatti McArthur Silvia

  公开号：US20090318474A1

  公开（公告）日：2009-12-24

  The present invention relates to compounds of formula (I), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders: wherein A, B, X, Y, R 1 , R 2 , R 3 and R 4 are as defined in the description and claims.

  本发明涉及化合物的公式（I），其制造过程，包含它们的药物组合物，以及用于治疗中枢神经系统疾病的方法：其中A、B、X、Y、R1、R2、R3和R4如描述和权利要求所定义。
• PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS
  申请人：McArthur Silvia Gatti

  公开号：US20080280924A1

  公开（公告）日：2008-11-13

  The present invention relates to compounds of formula (I) wherein A, B, Q, X, Y, R 1 , and R 2 are as defined herein; pharmaceutical compositions containing them; a process for their manufacture; and methods for treating CNS disorders with the same.

  本发明涉及式(I)的化合物，其中A、B、Q、X、Y、R1和R2如本文所定义；含有它们的药物组成物；它们的制备方法；以及使用它们治疗中枢神经系统疾病的方法。
• PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS
  申请人：Wang Tiansheng

  公开号：US20110053916A1

  公开（公告）日：2011-03-03

  The present invention relates to compounds useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the inventions and

  本发明涉及用于治疗结核病的抑制剂化合物。该发明还提供了制备该发明化合物的方法。